Gene Therapy for Ovarian Cancer-A Pipeline Analysis Report

About Gene Therapy
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.

Gene Therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy, which replaces faulty genes with normal ones in the body, is particularly promising and currently gaining attention. It has potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.

Download PDF Sample of Gene Therapy for Ovarian Cancer Market Report@ http://orbisresearch.com/contacts/request-sample/2027829

Covered in this report
The report covers the present scenario and the growth prospects of the gene therapy for ovarian cancer for 2018-2022. To calculate the market size, the report considers the revenue generated from the gene therapy.

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Takara Bio
• VBL
• Therapeutics
• Targovax
• CELSION
• Lokon Pharma
• SiBiono GeneTech
• Advantagene

Browse Full Report with TOC: http://orbisresearch.com/reports/index/gene-therapy-for-ovarian-cancer-a-pipeline-analysis-report

Market trend
• The adoption of replacement gene therapy
• For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Companies Mentioned:
Takara Bio, VBL, Therapeutics, Targovax, CELSION, Lokon Pharma, SiBiono GeneTech, and Advantagene

Place Purchase Order for this Report@ http://orbisresearch.com/contact/purchase/2027829

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GENE THERAPY FOR OVARIAN CANCER: AN INSIGHT
Introduction

PART 05: MAJOR REGULATORY AUTHORITIES
US
Europe
Japan
Australia
China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS
Mid-stage molecules (Phase II and I/II), 2017
Early-stage molecules (Phase I), 2017
Inactive molecules, 2017

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 10: THERAPEUTIC ASSESSMENT (BY TARGET)

PART 11: KEY COMPANIES
Active companies: Category and parameters
APPENDIX
List of abbreviations

Orbis Research is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required Market research study for our clients.

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: sales@orbisresearch.com

This release was published on openPR.